ES2194860T3 - Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada. - Google Patents

Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.

Info

Publication number
ES2194860T3
ES2194860T3 ES94901265T ES94901265T ES2194860T3 ES 2194860 T3 ES2194860 T3 ES 2194860T3 ES 94901265 T ES94901265 T ES 94901265T ES 94901265 T ES94901265 T ES 94901265T ES 2194860 T3 ES2194860 T3 ES 2194860T3
Authority
ES
Spain
Prior art keywords
timosine
suffer
patients
treatment
intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94901265T
Other languages
English (en)
Inventor
Paul B Chretien
Milton G Mutchnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Sciclone Pharmaceuticals LLC
Original Assignee
Wayne State University
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Sciclone Pharmaceuticals LLC filed Critical Wayne State University
Priority claimed from PCT/US1993/010619 external-priority patent/WO1995012405A1/en
Application granted granted Critical
Publication of ES2194860T3 publication Critical patent/ES2194860T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

UN METODO Y UNA COMPOSICION PARA TRATAR UN PACIENTE CON HEPATITIS B QUE TIENE UNA DESCOMPENSACION HEPATICA UTILIZA CANTIDADES REDUCTORAS DE VIRUS DE HEPATITIS B DE T{SUB,{AL}1}, ADMINISTRANDOSELO A UN PACIENTE QUE TIENE UNA ENFERMEDAD DE RIÑON DESCOMPENSADA DE MANERA QUE EL PACIENTE ES SERONEGATIVO PARA EL ADN DEL VIRUS DE LA HEPATITIS B.
ES94901265T 1993-11-05 1993-11-05 Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada. Expired - Lifetime ES2194860T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1993/010619 WO1995012405A1 (en) 1993-11-05 1993-11-05 Method and composition for treatment of patients having decompensated liver disease

Publications (1)

Publication Number Publication Date
ES2194860T3 true ES2194860T3 (es) 2003-12-01

Family

ID=22237139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94901265T Expired - Lifetime ES2194860T3 (es) 1993-11-05 1993-11-05 Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.

Country Status (10)

Country Link
EP (1) EP0731710B1 (es)
KR (1) KR100298859B1 (es)
CA (1) CA2175337C (es)
DE (1) DE69332982T2 (es)
DK (1) DK0731710T3 (es)
ES (1) ES2194860T3 (es)
MX (1) MXPA94003453A (es)
MY (1) MY111342A (es)
NO (1) NO961775L (es)
PT (1) PT731710E (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (es) * 1991-09-13 1994-05-21 Paul B Chretien
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU4671193A (en) * 1992-07-13 1994-01-31 Kenneth E. Sherman Composition and method of treating hepatitis b

Also Published As

Publication number Publication date
EP0731710A1 (en) 1996-09-18
EP0731710B1 (en) 2003-05-14
KR960706352A (ko) 1996-12-09
NO961775D0 (no) 1996-05-02
CA2175337C (en) 2000-06-20
NO961775L (no) 1996-05-02
DK0731710T3 (da) 2003-06-16
DE69332982T2 (de) 2004-09-09
HK1021685A1 (en) 2000-06-23
CA2175337A1 (en) 1995-05-11
DE69332982D1 (de) 2003-06-18
MXPA94003453A (es) 2004-08-16
EP0731710A4 (en) 1999-12-22
MY111342A (en) 1999-11-30
KR100298859B1 (ko) 2001-10-22
PT731710E (pt) 2003-09-30

Similar Documents

Publication Publication Date Title
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
ES2186660T3 (es) Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ES2124225T3 (es) Tratamiento de la disfuncion erectil.
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
BR0109716A (pt) Uso de um nucleosìdeo ou um análogo de nucleosìdeo no tratamento de infecção viral por hepatite delta
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
SE7900136L (sv) Flytbarhetshjelpmedel
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
EP1037918A4 (en) METHOD AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINALS USING CHEMOKINES
PT1115420E (pt) Tratamento de infeccao de hepatite b com timosina alfa 1 e lamivudine
ES2194860T3 (es) Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
ES2211996T3 (es) Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis.
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.
MX9201288A (es) Metodo de tratamiento.
ES2089371T3 (es) Vacuna contra las enfermedades respiratorias para gatos.
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
KR970019821A (ko) 송진을 함유한 치약 제조 방법